Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Not Recruiting

Trial ID: NCT02700529


This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema.

Official Title

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Stanford Investigator(s)

Stanley G. Rockson, MD
Stanley G. Rockson, MD

Allan and Tina Neill Professor of Lymphatic Research and Medicine


Inclusion Criteria:

   1. Has a diagnosis of secondary leg lymphedema, based on a positive lymphoscintigraphy
   (LSG) study of the affected leg OR has a diagnosis of primary lymphedema not of
   congenital onset affecting one or both lower limbs, based on positive LSG.

   2. Swelling of at least 1 leg not completely reversed by leg elevation or compression.

   3. Stage II or greater lymphedema, based on the International Society of Lymphology (ISL)
   staging system.

   4. Completion of a full course of complete decongestive therapy (CDT).

   5. Stable limb volume (within 10% during screening for worse/affected leg) .

   6. If patient has had a lymphatic vascularization procedure (lymphovenous bypass or lymph
   node transfer) or liposuction for lymphedema in the affected limb, then procedure must
   have been performed at least 1 year (12 months) prior to Screening AND affected limb
   must be clinically stable over the 3 months prior to Screening AND significant
   residual disease must be present.

   7. Ambulatory status (use of a walking aid is permitted).

   8. Agree to use a medically acceptable method of contraception, if the possibility of
   conception exists.

Exclusion Criteria:

Exclusions Based on Lymphedema:

   1. A diagnosis of primary lymphedema with congenital onset. Primary lymphedema is defined
   as lymphedema with onset prior to or without an inciting event (e.g, surgery, trauma,

   2. Occurrence of significant lymphedema of another body part that is not the lower limb
   (e.g, upper extremity, trunk, head and neck, genitalia).

   3. Lymphedema involving all four limbs

   4. Recent initiation of, or intention to initiate CDT or maintenance physiotherapy for

   Exclusions Based on Other Medical Conditions

   5. Deep venous thrombosis in either lower limb or systemic anticoagulation within 6

   6. Other medical condition that could lead to acute or chronic leg edema.

   7. Other medical condition that could result in symptoms overlapping those of lymphedema
   in the affected leg.

   8. History of clotting disorder (hypercoagulable state).

   9. Chronic (persistent) infection in either lower limb.

10. Cellulitis or other infection in either lower limb or use of antibiotics for
   cellulitis within 3 months prior to screening.

11. Other unstable or severe medical condition requiring active management and/or likely
   to decompensate/require active management within the next year

12. Current evidence of malignancy.

13. History of malignancy within the previous 3 years, except for nonmelanoma skin cancer
   or cervical carcinoma in situ treated with curative intent.

14. Currently receiving chemotherapy or radiation therapy.

15. Life expectancy < 2 years for any reason.

16. Pregnancy or nursing.

17. Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening.

   Exclusions Based on Concurrent Medication Use

18. Regular concurrent use or regular use within 6 months before screening of another
   leukotriene pathway inhibitor.

19. Concurrent antibiotic use.

20. Concurrent use of any agent active on the sphingosine-1-phosphate (S1P) pathway.

21. Concurrent use of unapproved (including herbal) treatments for lymphedema.

   Exclusions Based on Laboratory Values

22. Significant or chronic renal insufficiency or requires dialytic support.

23. Hepatic dysfunction.

24. Absolute neutrophil count <1500 mm3 at screening.

25. Hemoglobin concentration <9 g/dL at screening.


drug: ubenimex

other: placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eric Henderson